Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER-2 Protein Overexpression”

70 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 70 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05480384
What this trial is testing

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

Who this might be right for
Esophageal AdenocarcinomaEsophageal CancerHER-2 Protein Overexpression+1 more
Brown University 1
Testing effectiveness (Phase 2)UnknownNCT05135715
What this trial is testing

RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)

Who this might be right for
Melanoma, Stage IIHER2-positiveAdvanced Melanoma
RemeGen Co., Ltd. 50
Testing effectiveness (Phase 2)WithdrawnNCT01427244
What this trial is testing

Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease

Who this might be right for
Paget's Disease of the Vulva
Yale University
Testing effectiveness (Phase 2)Looking for participantsNCT05315700
What this trial is testing

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Who this might be right for
Solid Tumors
ORIC Pharmaceuticals 350
Early research (Phase 1)WithdrawnNCT04602117
What this trial is testing

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Who this might be right for
HER2-positive Breast CancerHER2 LowSYD-985+24 more
QuantumLeap Healthcare Collaborative
Very early researchWithdrawnNCT02735798
What this trial is testing

64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets

Who this might be right for
Brain MetastasesDocumented Her2 OverexpressionAdvanced Solid Tumor+1 more
Pamela Munster
Testing effectiveness (Phase 2)UnknownNCT06055153
What this trial is testing

DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC

Who this might be right for
Esophageal Squamous CarcinomaHER-2 Protein Overexpression
Changhai Hospital 20
Not applicableActive Not RecruitingNCT02295059
What this trial is testing

Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention

Who this might be right for
Breast Cancer
City of Hope Medical Center 80
Not applicableUnknownNCT02136836
What this trial is testing

Investigation of the Proportion of Human Epidermal Growth Factor Receptor 2 Protein Overexpression of Gastric Adenocarcinoma and Prognostic Effect of HER2, and Analysis of Practice Pattern of Herceptin Use in Stage IV Gastric Cancer

Who this might be right for
Stomach Neoplasms
Yonsei University 860
Early research (Phase 1)Looking for participantsNCT04995003
What this trial is testing

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

Who this might be right for
SarcomaHER-2 Protein OverexpressionOsteosarcoma+5 more
Baylor College of Medicine 25
Large-scale testing (Phase 3)Study completedNCT00281658
What this trial is testing

Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 444
Testing effectiveness (Phase 2)UnknownNCT05627414
What this trial is testing

Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer

Who this might be right for
Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)WithdrawnNCT04464967
What this trial is testing

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Who this might be right for
Advanced Solid TumorMetastatic CancerHER2-positive Breast Cancer+14 more
NKGen Biotech, Inc.
Testing effectiveness (Phase 2)Study completedNCT00033514
What this trial is testing

Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression

Who this might be right for
Breast Cancer
Jonsson Comprehensive Cancer Center 27
Large-scale testing (Phase 3)UnknownNCT04714190
What this trial is testing

RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

Who this might be right for
Gastric CancerHER2 Overexpressing Gastric Carcinoma
RemeGen Co., Ltd. 351
Testing effectiveness (Phase 2)Looking for participantsNCT06560528
What this trial is testing

Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
Tianjin Medical University Cancer Institute and Hospital 40
Early research (Phase 1)Looking for participantsNCT07361562
What this trial is testing

A Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor, AdultERBB2 Altered Breast CancerERBB2 Gene Amplification+3 more
Cogent Biosciences, Inc. 100
Early research (Phase 1)Ended earlyNCT00251433
What this trial is testing

GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 53
Early research (Phase 1)Active Not RecruitingNCT04692831
What this trial is testing

Testing a New Imaging Agent to Identify Cancer

Who this might be right for
HER-2 Positive Malignant Carcinoma of BreastHER-2 Protein OverexpressionHER2-positive Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center 60
Not applicableEnded earlyNCT02840110
What this trial is testing

Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product

Who this might be right for
B Cell LymphomasMultiple MyelomaSolid Tumor+1 more
Cogent Biosciences, Inc. 22
Load More Results